Group 1 - The company reported a revenue of RMB 158 million for the year ending December 31, 2024, representing a 9% decrease year-on-year [1] - The net loss for the year was RMB 591 million, a reduction of 23.1% compared to the previous year [1] - Research and development expenses amounted to RMB 283 million, down 31.58% year-on-year [1] - The loss per share was RMB 1.43 [1] Group 2 - The company achieved significant progress in developing, producing, and commercializing cell immunotherapy products, with operational efficiency improvements such as stable gross margins and reduced cash outflows [2] - The leading product, Benauda®, continued to make progress in commercialization, with approvals from the National Medical Products Administration (NMPA) for clinical trials in specific patient groups [2] - Benauda® became the first cell therapy product approved in China for treating r/r Mantle Cell Lymphoma (MCL) patients [2] - The company has established a strong commercial team responsible for the commercialization of Benauda® in China, enhancing its sales, marketing, and market access capabilities [2]
药明巨诺-B(02126)发布年度业绩，收入1.58亿元 预计下一期间倍诺达®的销售收入会再次增加